ProShares Ultra NASDAQ Biotechnology
BIB
20 hedge funds and large institutions have $15.6M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 3 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
337% more capital invested
Capital invested by funds: $3.58M → $15.6M (+$12M)
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
82% more funds holding
Funds holding: 11 → 20 (+9)
15% less call options, than puts
Call options by funds: $8.1M | Put options by funds: $9.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
+$4.43M |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$2.72M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.37M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.55M |
| 5 |
AIG
American International Group
New York
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prelude Capital Management
New York
|
-$1.14M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$89.9K |
| 3 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
-$5K |
| 4 |
PFG
Piershale Financial Group
Barrington,
Illinois
|
-$3K |
BIB Hedge Fund Activity: Q1 2014 in Review
20 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2014, worth a combined $15.6M — up 337% from $3.58M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BIB positions and 3 closed out — a net gain of 9 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Valentine Capital Asset Management, adding an estimated $4.43M. The largest seller was Prelude Capital Management, exiting entirely with an estimated $1.14M sold.
- 20 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2014, up from 11 in Q4 2013.
- Funds reported $15.6M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2014, up 337% quarter-over-quarter.
- 12 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2014 and 3 closed out, a net change of +9 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2014 was Valentine Capital Asset Management, an estimated $4.43M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2014 was Prelude Capital Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q1 2014.